DaVita - 15 Year Stock Price History | DVA
Historical daily share price chart and data for DaVita since 2011 adjusted for splits and dividends. The latest closing stock price for DaVita as of June 17, 2026 is 210.58.
- The all-time high DaVita stock closing price was 210.58 on June 17, 2026.
- The DaVita 52-week high stock price is 213.32, which is 1.3% above the current share price.
- The DaVita 52-week low stock price is 101.00, which is 52% below the current share price.
- The average DaVita stock price for the last 52 weeks is 141.50.
| DaVita Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 155.0017 | 114.5100 | 210.5800 | 103.8700 | 210.5800 | 85.35% |
| 2025 | 139.1218 | 149.8200 | 177.3500 | 113.5000 | 113.6100 | -24.03% |
| 2024 | 140.8322 | 106.8900 | 167.9600 | 103.8900 | 149.5500 | 42.75% |
| 2023 | 91.8691 | 74.8400 | 112.6800 | 73.2000 | 104.7600 | 40.30% |
| 2022 | 94.5861 | 115.4300 | 123.3800 | 65.4200 | 74.6700 | -34.36% |
| 2021 | 115.5906 | 116.5000 | 133.7800 | 94.5000 | 113.7600 | -3.10% |
| 2020 | 86.0846 | 75.2500 | 117.4000 | 64.9900 | 117.4000 | 56.47% |
| 2019 | 57.9482 | 51.7300 | 75.0300 | 43.4200 | 75.0300 | 45.80% |
| 2018 | 68.7052 | 72.5400 | 80.0300 | 48.7300 | 51.4600 | -28.78% |
| 2017 | 63.5263 | 65.0900 | 72.3600 | 53.8900 | 72.2500 | 12.54% |
| 2016 | 68.9896 | 68.6700 | 78.4400 | 55.1600 | 64.2000 | -7.90% |
| 2015 | 77.4037 | 75.8300 | 84.2300 | 67.7900 | 69.7100 | -7.96% |
| 2014 | 71.1832 | 64.7800 | 78.0700 | 62.7400 | 75.7400 | 19.52% |
| 2013 | 59.1146 | 54.6000 | 65.5950 | 53.7550 | 63.3700 | 14.67% |
| 2012 | 47.3399 | 38.5650 | 57.4900 | 38.5650 | 55.2650 | 45.80% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $10.023B | $13.643B |
| DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |